After years of underperformance, the SPDR S&P Biotech ETF (XBI) is finally making a strong comeback. On the monthly chart, the ETF has been consolidating below a crucial resistance zone around $106–$107, which has acted as a major pivot since 2018. This level served as solid support before the 2021 peak, and now, after several years of sideways movement, XBI is once again knocking on the door of a potential multi-month breakout. A confirmed breakout and close above $107 could signal a major shift in trend — potentially launching the biotech sector into a sustained bull cycle

Trading isn’t always about luck—it’s about spotting intentional money moves before the crowd catches on. That’s exactly what happened with Deckers Outdoor Corp (DECK) this week. On July 21st, 2025, I noticed a highly unusual options trade pop up on my Unusual Whales scanner: 🟣 500 DECK $114 Calls expiring July 25th were swept at the ASK for $2.58 💰 Total Premium: $129K 📊 Volume/Open Interest ratio: 507/75 (6.76x) ⏳ Expiration: Only 3 days away 🔍 Code: SLAN (Sweep, Large, at Ask, Near-expiry) Let’s break down why this mattered. 🚩 Why This Flow Screamed “PAY ATTENTION” 🎯

The fields of gene editing and synthetic biology are no longer science fiction—they are the next frontier of medicine, agriculture, and industrial manufacturing. As breakthroughs like CRISPR-Cas9 and cell programming become real-world solutions, investors are turning their attention to this revolutionary sector. In this post, we’ll break down what these technologies are, why they matter, and which publicly traded gene editing and synthetic biology companies you should be watching right now. 🚀 Why Gene Editing & Synthetic Biology Matter What is Gene Editing? Gene editing allows scientists to precisely modify DNA within cells. The most well-known technique,